Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Response to 'Energy balance measurement: when something is not better than nothing'.

Dhurandhar NV, Schoeller DA, Brown AW, Heymsfield SB, Thomas D, Sørensen TI, Speakman JR, Jeansonne M, Allison DB; Energy Balance Measurement Working Group.

Int J Obes (Lond). 2015 Jul;39(7):1175-6. doi: 10.1038/ijo.2015.81. Epub 2015 Apr 30. No abstract available.

2.

Reply: To PMID 24375485.

Verrijken A, Francque S, Mertens I, Gaal LV.

Hepatology. 2014 Oct;60(4):1451. doi: 10.1002/hep.27167. Epub 2014 May 19. No abstract available.

PMID:
24723433
3.

Distribution of persistent organic pollutants in two different fat compartments from obese individuals.

Malarvannan G, Dirinck E, Dirtu AC, Pereira-Fernandes A, Neels H, Jorens PG, Gaal LV, Blust R, Covaci A.

Environ Int. 2013 May;55:33-42. doi: 10.1016/j.envint.2013.02.012. Epub 2013 Mar 19.

PMID:
23518385
4.

Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators.

N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3.

5.

N-glycan based biomarker distinguishing non-alcoholic steatohepatitis from steatosis independently of fibrosis.

Blomme B, Francque S, Trépo E, Libbrecht L, Vanderschaeghe D, Verrijken A, Pattyn P, Nieuwenhove YV, Putte DV, Geerts A, Colle I, Delanghe J, Moreno C, Gaal LV, Callewaert N, Vlierberghe HV.

Dig Liver Dis. 2012 Apr;44(4):315-22. doi: 10.1016/j.dld.2011.10.015. Epub 2011 Nov 25.

PMID:
22119618
6.

Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial.

Maggioni AP, Caterson I, Coutinho W, Finer N, Gaal LV, Sharma AM, Torp-Pedersen C, Bacher P, Shepherd G, Sun R, James P; SCOUT Investigators.

J Cardiovasc Pharmacol. 2008 Nov;52(5):393-402. doi: 10.1097/FJC.0b013e31818713d6.

PMID:
19033818
7.

Sleep-disordered breathing: a new risk factor of suspected fatty liver disease in overweight children and adolescents?

Verhulst SL, Jacobs S, Aerts L, Schrauwen N, Haentjens D, Rooman RP, Gaal LV, De Backer WA, Desager KN.

Sleep Breath. 2009 May;13(2):207-10. doi: 10.1007/s11325-008-0231-5. Epub 2008 Nov 11.

PMID:
19002513

Supplemental Content

Loading ...
Support Center